Bell Bank Sells 38,966 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Bell Bank has reduced its stake in Gilead Sciences by 33.5%, holding 77,196 shares valued at approximately $8.56 million after selling nearly 39,000 shares during the second quarter.
• Gilead Sciences reported $2.01 EPS for the most recent quarter, slightly exceeding consensus estimates, with revenues of $7.08 billion.
• The company will deliver a quarterly dividend of $0.79 per share on September 29th, representing an annualized yield of 2.8%.

Bell Bank trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 77,196 shares of the biopharmaceutical company's stock after selling 38,966 shares during the period. Bell Bank's holdings in Gilead Sciences were worth $8,559,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new position in Gilead Sciences during the 4th quarter valued at about $215,000. Vise Technologies Inc. boosted its holdings in Gilead Sciences by 30.5% during the 4th quarter. Vise Technologies Inc. now owns 26,838 shares of the biopharmaceutical company's stock valued at $2,479,000 after acquiring an additional 6,276 shares during the period. Fourth Dimension Wealth LLC purchased a new position in Gilead Sciences during the 4th quarter valued at about $54,000. Finally, Sunbelt Securities Inc. boosted its holdings in Gilead Sciences by 6.2% during the 4th quarter. Sunbelt Securities Inc. now owns 16,680 shares of the biopharmaceutical company's stock valued at $1,535,000 after acquiring an additional 977 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a report on Friday, July 25th. Royal Bank Of Canada boosted their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, September 16th. Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Finally, Rothschild & Co Redburn boosted their price target on Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $117.17.

Gilead Sciences Price Performance

NASDAQ:GILD traded up $0.32 during trading hours on Tuesday, reaching $112.81. 1,215,429 shares of the company's stock were exchanged, compared to its average volume of 8,051,165. The company has a market capitalization of $139.97 billion, a P/E ratio of 22.43, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. Gilead Sciences, Inc. has a 12 month low of $81.83 and a 12 month high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The business's 50-day simple moving average is $114.11 and its two-hundred day simple moving average is $109.95.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the transaction, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $9,390,030 in the last quarter. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.